A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients With Asthma
Phase of Trial: Phase III
Latest Information Update: 23 May 2017
At a glance
- Drugs Glycopyrrolate/indacaterol/mometasone (Primary)
- Indications Asthma
- Focus Adverse reactions; Registrational
- Sponsors Novartis Pharmaceuticals
- 16 May 2017 Planned primary completion date changed from 31 May 2019 to 6 Nov 2018.
- 16 May 2017 Status changed from not yet recruiting to recruiting.
- 07 Apr 2017 New trial record